

- 6 -

### CLAIMS

1. Ibopamine maleate salt (1:1).
2. Pharmaceutical composition for ophthalmic use, characterized in that it comprises ibopamine maleate (1:1) together with at least one pharmaceutically acceptable vehicle.
3. Pharmaceutical composition according to Claim 2, characterized in that it is in the form of an ointment or eyedrops.
4. Pharmaceutical composition according to Claim 2 or 3, characterized in that the amount of ibopamine is between 0.01% and 6% by weight.
5. Pharmaceutical composition according to Claim 2 or 3, characterized in that the amount of ibopamine is between 0.1% and 5% by weight.
6. Process for preparing the ibopamine maleate salt (1:1), characterized in that it includes the addition of maleic acid, dissolved in a suitable organic solvent, to ibopamine base, also dissolved in a suitable organic solvent, in a 1:1 molar ratio.
7. Process according to Claim 6, characterized in that the abovementioned addition is performed under an atmosphere of an inert gas.
8. Process according to Claim 6 or 7, characterized in that the abovementioned addition is performed at room temperature.
9. Process according to any one of the preceding Claims 6 to 8, characterized in that the salt formed is isolated via precipitation and filtration.
10. Process according to any one of the preceding Claims 6 to 9, characterized in that the abovementioned organic solvent is acetone.
11. Process according to Claim 10, characterized in that the salt is precipitated from the acetone solution via addition of ethyl ether.